Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

Recruiting Observational Study
Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Becker Muscular Dystrophy Carrier of Duchenne Muscular Dystrophy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
Vanderbilt University Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objectives of this proposal are to elucidate this evolution of heart dysfunction and identify measures from cardiac MRI images …
Trial Locations

Sorted by distance from Montana

Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Clinical phenotype of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or muscular dystrophy carrier (MDC) confirmed with muscle biopsy or genotype Exclusion Criteria: * Additional genetic or congenital abnormality that may affect cardiovascular function o…
Contacts

Jonathan Soslow, MD, MSCI

615-322-7447

DMDMachineLearning@vumc.org

CONTACT